You are here

LEE011

Investigational Breast Cancer Drug Could Boost Novartis’s Position

Marketwatch

Mon, 04/3/17 - 11:52 am

Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer

Endpoints

Tue, 03/14/17 - 09:38 am

Novartis pill gets U.S. breakthrough designation in breast cancer

Yahoo/Reuters

Wed, 08/3/16 - 09:14 am

breakthrough therapies

The mano-a-mano between Pfizer's Ibrance and Novartis' LEE011 nears with early PhIII wrap-up

Fierce Pharma

Wed, 05/18/16 - 04:27 pm

clinical trials

Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race

Seeking Alpha

Mon, 04/14/14 - 08:20 am

3 Breast Cancer Drugs With Big Potential

Motley Fool

Thu, 04/10/14 - 10:37 am

CDK 4/6 inhibitors

Pfizer Feels the Heat From Novartis

Wall St Cheat Sheet

Sat, 11/23/13 - 12:45 pm

Pfizer Vs. Novartis: A New Era In Breast Cancer Treatment

Seeking Alpha

Thu, 10/31/13 - 09:38 am

Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib

Fierce Biotech

Mon, 10/21/13 - 05:55 pm

cyclin-dependent kinase inhibition [CDK]